Evidence map›Paper›PMID 39695102›Full record

ArticleCell death & disease2024

Tumor- and host-derived heparanase-2 (Hpa2) attenuates tumorigenicity: role of Hpa2 in macrophage polarization and BRD7 nuclear localization.

Soaad Soboh, Avital Vorontsova, Malik Farhoud, Uri Barash, Inna Naroditsky, Miriam Gross-Cohen, Marina Weissmann, Yasuhiko Nishioka, Adrian S Woolf, Neil A Roberts and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. The Pathophysiological Functions of Heparanases: From Evolution, Structural and Tissue-Specific Perspectives.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Soaad SobohTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Avital VorontsovaTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Malik FarhoudTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Uri BarashTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Inna NaroditskyDepartments of Pathology, Rambam Health Care Campus, Haifa, Israel.
Miriam Gross-CohenTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Marina WeissmannTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Yasuhiko NishiokaDepartment of Respiratory Medicine and Rheumatology, Tokushima University, Tokushima, Japan.
Adrian S WoolfDivision of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.
Neil A RobertsDivision of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.
Yuval ShakedTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Neta IlanTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Israel VlodavskyTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel. vlodavsk@technion.ac.il.

Funding

Medical Research Council APP14742Medical Research Council MR/Y008340/1
6 · The paper itself

Abstract

Little attention was given to heparanase 2 (Hpa2) over the last two decades, possibly because it lacks a heparan sulfate (HS)-degrading activity typical of heparanase. Emerging results suggest, nonetheless, that Hpa2 plays a role in human pathologies, including cancer progression where it functions as a tumor suppressor. Here, we examined the role of Hpa2 in cervical carcinoma. We report that high levels of Hpa2 correlate with prolonged survival of cervical carcinoma patients. Strong staining intensity of Hpa2 also correlates with low tumor grade. Overexpression of Hpa2 in SiHa cervical carcinoma cells resulted in tumor xenografts that were two-fold smaller than control tumors. Interestingly, even smaller tumor xenografts were developed by SiHa cells overexpressing the Pro140Arg and Asn543Ile Hpa2 missense mutations that were identified in patients diagnosed with urofacial syndrome (UFS). Utilizing the Ras recruitment system, we identified bromodomain-containing protein 7 (BRD7) to interact with Hpa2 and found that both BRD7 and the Hpa2 mutants are translocated to the cell nucleus in tumors developed by the Pro140Arg and Asn543Ile Hpa2 mutants. Utilizing our newly developed conditional Hpa2-KO mice, we further show that Hpa2 plays a critical role in macrophage polarization; in the absence of Hpa2, macrophages are shifted towards pro-tumorigenic, M2 phenotype. Notably, implanting SiHa cervical carcinoma cells together with Hpa2-KO macrophages promoted tumor growth. These results support, and further expand, the notion that Hpa2 functions as a tumor suppressor, co-operating with another tumor suppressor, BRD7.

Indexed as

Cell NucleusGlucuronidaseMacrophagesUterine Cervical NeoplasmsAnimalsCarcinogenesisCell Line, TumorFemaleHeparanaseHumansMiceGlucuronidaseHeparanase

Identifiers

PMID39695102
PMCPMC11655850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.